The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic impact of phosphorylated HER2 in HER2-positive primary breast cancer using reverse-phase protein array.
N. Hayashi
No relevant relationships to disclose
T. Iwamoto
No relevant relationships to disclose
A. M. Gonzalez-Angulo
No relevant relationships to disclose
J. Ferrer-Lozano
No relevant relationships to disclose
A. Lluch
No relevant relationships to disclose
N. Niikura
No relevant relationships to disclose
C. Bartholomeusz
No relevant relationships to disclose
S. Nakamura
No relevant relationships to disclose
G. N. Hortobagyi
No relevant relationships to disclose
N. T. Ueno
No relevant relationships to disclose